BrightSpring Health (BTSG) PT Raised to $26 at Mizuho

Mizuho analyst Ann Hynes raised the price target on BrightSpring Health (NASDAQ: BTSG) to $26.00 (from $22.00) while maintaining a Outperform rating.

The analyst commented: "We are raising our price target to $26 from $22 and 2025E-2027E adjusted EBITDA estimates after a solid Q1:25 and guidance raise. We believe this was a solid start to 2025 for BTSG and continue to believe there is more upside potential than downside risk given the company's leverage to specialty drugs and the oncology generic pipeline. We reiterate our Outperform rating."

You May Also Be Interested In

• PBF Energy (PBF) PT Raised to $57 at Mizuho
• Guggenheim Starts BrightSpring Health (BTSG) at Buy
• Agenus Inc. (AGEN) PT Raised to $30 at H.C. Wainwright